Advances in biomarker testing, molecular diagnostics and genomic analysis are changing how disease is identified and treated. By revealing information about the biological characteristics of a disease, these technologies can help clinicians make more informed decisions and identify patients who may benefit from specific treatments.
However, the value of a diagnostic test depends on more than its technological capabilities. Its results must be reliable, its performance properly evaluated and its intended use supported by appropriate evidence.
As National Pathology Week runs from 2-8 November, it is an opportunity to consider the increasingly important relationship between diagnostic innovation, laboratory quality and regulatory oversight.
From detecting disease to guiding treatment
Traditional diagnostic testing has long played a central role in identifying disease and monitoring its progression. Advances in molecular and genomic technologies are extending that role, helping clinicians understand not only whether a disease is present, but also its underlying characteristics.
In cancer care, for example, biomarker testing can identify particular molecular changes that may influence treatment selection. This supports a more targeted approach, in which treatment decisions can be informed by the biological profile of an individual’s disease.
Other developments, including liquid biopsies and increasingly sophisticated molecular tests, are creating further opportunities to detect and monitor disease. As these technologies progress, diagnostics are becoming an increasingly important part of the wider development and use of precision medicines.
Yet a promising technology does not automatically translate into a clinically useful test. Establishing what a test can reliably detect, how accurately it performs and whether its results are meaningful in the intended patient population remains essential.
Why analytical and clinical performance matter
For diagnostic developers, demonstrating performance involves more than showing that a test produces a result.
Analytical performance concerns how reliably a test measures or detects its intended target. Depending on the test, this may include its accuracy, precision, sensitivity, specificity and ability to identify low levels of a biomarker.
Clinical performance considers how effectively the test identifies, predicts or monitors a particular clinical condition or outcome in the population for which it is intended.
These are related but distinct considerations. A test may reliably detect a biomarker, for example, without sufficient evidence that the result can predict how a patient will respond to a particular treatment.
The distinction is important when diagnostic results influence clinical decisions. Evidence must support not only the technology itself, but also the claims made about its intended use.
Validation does not end with development
Diagnostic performance must also be considered in the context in which a test will actually be used.
Laboratories may need to verify a manufacturer’s performance claims before introducing a device into routine use. Where a test is modified, used outside its stated instructions or incorporated into a laboratory-developed method, further validation may be necessary to establish that it remains fit for purpose.
The requirements will depend on the technology, its intended application and the circumstances of its use. Relevant considerations can include sample type, testing environment, workflow, operator competency and the potential consequences of an incorrect result.
Quality management is therefore integral to diagnostic reliability. Appropriate documentation, risk assessment, quality control and ongoing performance monitoring help laboratories identify potential problems and maintain confidence in results.
These considerations are particularly relevant as laboratories adopt newer technologies, including next-generation sequencing, digital pathology and AI-supported analytical systems.
The evolving regulatory landscape
As diagnostic technologies advance, demonstrating that tests are safe, reliable and fit for purpose remains essential.
In Great Britain, in vitro diagnostic medical devices are regulated under the UK Medical Devices Regulations 2002, as amended. Manufacturers need to understand the requirements relevant to their products early in development, ensuring that appropriate evidence, risk management and quality processes are in place.
These considerations are becoming particularly important as laboratories adopt newer technologies and adapt existing tests for different applications. Recent joint guidance from the IBMS, LabMed and MHRA, with input from UKAS, highlights the importance of appropriate validation and verification, including when diagnostic devices are modified or used in laboratory-developed testing.
The aim is to support innovation while maintaining confidence in diagnostic results. Robust evidence and quality processes are not simply regulatory requirements; they are fundamental to ensuring that tests can reliably inform clinical decisions.
Turning diagnostic innovation into clinical value
The future of precision medicine will depend partly on the ability to translate advances in diagnostic science into reliable tools that can be used effectively in practice.
That requires collaboration between diagnostic developers, pharmaceutical and biotechnology companies, laboratories, healthcare professionals and regulatory specialists. It also requires a clear understanding of the evidence needed at each stage, from early development through to routine use and ongoing performance monitoring.
National Pathology Week recognises the contribution of pathology and laboratory science to healthcare. It also provides an opportunity to reflect on what makes diagnostic innovation meaningful: not simply the ability to generate more data, but the confidence that those results are accurate, relevant and capable of supporting informed decisions.
For the life sciences sector, robust evidence, quality and regulatory planning are not obstacles to innovation. They are essential to translating scientific progress into dependable diagnostic tools and better-informed treatment decisions.
Back to News + Insights